Initial evaluation of nighttime restlessness in a naturally occurring @entity235 model of XXXX .

@entity1 @entity571 @entity235 @entity158 @entity1118 @entity25
@entity1118 due to @entity571 ( @entity571 ) can lead to significant @entity25 and increased restlessness. Our objective was to assess whether naturally occurring @entity235 @entity571 is associated with nighttime restlessness and so has potential as a model of @entity25 . The study was designed as a two-part prospective masked, placebo-controlled study using client-owned @entity235 (Part A n = 60; Part B n = 19). Inclusion criteria consisted of @entity571 -associated joint @entity158 . The primary outcome measure for both parts was nighttime accelerometry. In Part B, quality of sleep was assessed using a clinical metrology instrument (Sleep and Night Time Restlessness Evaluation Score, SNoRE). Part A included @entity235 receiving two weeks of non-steroidal anti-inflammatory drug (NSAID) preceded with two weeks of no treatment. Part B was a crossover study, with NSAID/placebo administered for two weeks followed by a washout period of one week and another two weeks of NSAID/placebo. Repeated measures analysis of variance was used to assess differences between baseline and treatment. There were no significant changes in accelerometry-measured nighttime activity as a result of NSAID administration. SNoRE measures indicated significant improvements in aspects of the quality of nighttime sleep that did not involve obvious movement. These results reflect the few similar studies in @entity1 @entity571 @entity1 . Although accelerometry does not appear to be useful, this model has potential to model the @entity1 @entity158 -related nighttime @entity25 , and other outcome measures should be explored in this model.
